A Phase 2 interventional study of SHR-1210 and Apatinib in Small-cell Lung Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-08-07.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 365 studies in Small Cell Lung Carcinoma with a site in China — 183 open to participants now, 215 under way, 36 of them phase 3. Small Cell Lung Carcinoma · China.
Among the 365 studies in Small Cell Lung Carcinoma with a site in China, this one is the 186th largest by enrollment of the 333 interventional ones that give a count, is one of 16 that started in 2018, is one of 153 in phase 2, and was the 45th registered.
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
Browse Small Cell Lung Carcinoma studies →183 of the 365 studies in Small Cell Lung Carcinoma with a site in China are open now. Recruiting first, the newest first:
LI FENG · Sites in China
Ages 18+
Boehringer Ingelheim · Sites in China, United States, Australia and 8 more countries
Ages 18+
Qilu Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Shanghai Hengrui Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Boehringer Ingelheim · Sites in China, United States, Australia and 7 more countries
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
365 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 85 · Phase 2 200 · Phase 3 62 · Phase 4 7
First in 2001; this study’s year is marked. 16 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is close to the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Median enrollment 63 across the 333 interventional studies, 100 across the 31 observational. Of the 62 that completed or were terminated, 13 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
151 of 365 have an industry lead sponsor. The 10 most frequent:
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
Jiangsu HengRui Medicine Co., Ltd. has 7 studies filed under Small Cell Lung Carcinoma — fewer than ten, so there is no comparison to draw.
60 of the studies in Small Cell Lung Carcinoma with a site in China that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06500026Phase 3Sichuan Baili Pharmaceutical Co., Ltd.A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) | 2026-12 |
| NCT06961201Phase 3Changchun GeneScience Pharmaceutical Co., Ltd.Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase | 2026-12-31 |
| NCT06954246Phase 3Qilu Pharmaceutical Co., Ltd.A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | 2027-05 |
| NCT07881705Phase 3Jiangsu Simcere Pharmaceutical Co., Ltd.A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer | 2027-07-15 |
| NCT06095583Phase 3Shanghai Junshi Bioscience Co., Ltd.Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) | 2027-07-31 |
Add all 60 to your calendar (.ics) → With an account.
Among the 365 studies in Small Cell Lung Carcinoma with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, open-label, phase II study of intravenous (IV) SHR-1210 at 200mg,q2w in combination with Apatinib at one dose (375mg). Comparison of 3 different dose schedules in subjects with extensive-stage disease small cell lung cancer. SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1). Apatinib is a new kind of selective Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) tyrosine kinase inhibitor (TKI).
The study is composed of two parts. Part 1 of the study will determine the safety and tolerability of SHR-1210 in combination with Apatinib in first 6 subjects of each arm. The second phase of treatment was carried out by selecting one group of administration mode and the tolerated dose of Apatinib. Part 2 of the study will determine the safety and efficacy of SHR-1210 in combination with Apatinib in 39 subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD
Drug: SHR-1210 · Drug: Apatinib
SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD (5 Days on, 2 Days off)
Drug: SHR-1210 · Drug: Apatinib
SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD (7 Days on, 7 Days off)
Drug: SHR-1210 · Drug: Apatinib
Adverse Event
Evaluation of adverse event rate according to CTCAE v4.03
Time frame: 24 months
ORR
Objective response rate according to RECIST v1.1 (Response was assessed with CT or MRI using RECIST v1.1, Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to\<10 mm; Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Over all response:CR+PR)
Time frame: 6 months
OS Rate
Overall survival rate
Time frame: 6 months
PFS
Progression-free survival according to RECIST v1.1
Time frame: Imaging assessment was performed on C1D28 and every 8 weeks after C1D28 until radiographic progressive disease (PD) was documented.
TTR
Time to response according to RECIST v1.1 (Response was assessed with CT or MRI using RECIST v1.1, Time to response (TTR): date of first dose to date of first documented CR or PR)
Time frame: Imaging assessment was performed on C1D28 and every 8 weeks after C1D28 until radiographic progressive disease (PD) was documented.
DoR
Duration of response according to RECIST v1.1 (Response was assessed with CT or MRI using RECIST v1.1, Duration of response (DoR): DoR will only be performed in subjects who have a confirmed tumor response (CR or PR) after treatment
Time frame: Imaging assessment was performed on C1D28 and every 8 weeks after C1D28 until radiographic progressive disease (PD) was documented.
DCR
Disease control rate according to RECIST v1.1 (Response was assessed with CT or MRI using RECIST v1.1; Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to\<10 mm; Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Disease control rate (DCR): CR+PR+SD
Time frame: Imaging assessment was performed on C1D28 and every 8 weeks after C1D28 until radiographic progressive disease (PD) was documented.
OS
Overall survival
Time frame: on average of 2 years
| Milestone | A(SHR-1210+Apatinib) | B(SHR-1210+Apatinib) | C(SHR-1210+Apatinib) |
|---|---|---|---|
| Started | 47 | 6 | 6 |
| Completed | 47 | 6 | 6 |
| Not completed | 0 | 0 | 0 |
Evaluation of adverse event rate according to CTCAE v4.03
| participants | A(SHR-1210+Apatinib) | B(SHR-1210+Apatinib) | C(SHR-1210+Apatinib) |
|---|---|---|---|
| Adverse Event | 47 | 6 | 5 |
Objective response rate according to RECIST v1.1 (Response was assessed with CT or MRI using RECIST v1.1, Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to\<10 mm; Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Over all response:CR+PR)
| percentage of number of people in FAS | A(SHR-1210+Apatinib) | B(SHR-1210+Apatinib) | C(SHR-1210+Apatinib) |
|---|---|---|---|
| ORR | 34.0 (20.9 to 49.3) | 33.3 (4.3 to 77.7) | 33.3 (4.3 to 77.7) |
Overall survival rate
| percentage of number of people in FAS | A(SHR-1210+Apatinib) | B(SHR-1210+Apatinib) | C(SHR-1210+Apatinib) |
|---|---|---|---|
| OS Rate | 63.8 (48.4 to 75.7) | 66.7 (19.5 to 90.4) | 44.4 (6.6 to 78.5) |
Progression-free survival according to RECIST v1.1
| months | A(SHR-1210+Apatinib) | B(SHR-1210+Apatinib) | C(SHR-1210+Apatinib) |
|---|---|---|---|
| PFS | 3.6 (1.9 to 4.6) | 3.6 (2.7 to 8.3) | 1.2 (0.9 to 19.7) |
Time to response according to RECIST v1.1 (Response was assessed with CT or MRI using RECIST v1.1, Time to response (TTR): date of first dose to date of first documented CR or PR)
| months | A(SHR-1210+Apatinib) | B(SHR-1210+Apatinib) | C(SHR-1210+Apatinib) |
|---|---|---|---|
| TTR | 1.0 (0.9 to 4.7) | 1.8 (0.9 to 2.7) | 4.6 (0.9 to 8.2) |
Duration of response according to RECIST v1.1 (Response was assessed with CT or MRI using RECIST v1.1, Duration of response (DoR): DoR will only be performed in subjects who have a confirmed tumor response (CR or PR) after treatment
| months | A(SHR-1210+Apatinib) | B(SHR-1210+Apatinib) | C(SHR-1210+Apatinib) |
|---|---|---|---|
| DoR | 6.2 (3.7 to 9.2) | 4.2 (3.6 to 4.7) | 8.0 (4.6 to 11.5) |
Disease control rate according to RECIST v1.1 (Response was assessed with CT or MRI using RECIST v1.1; Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to\<10 mm; Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Disease control rate (DCR): CR+PR+SD
| percentage of number of people in FAS | A(SHR-1210+Apatinib) | B(SHR-1210+Apatinib) | C(SHR-1210+Apatinib) |
|---|---|---|---|
| DCR | 68.1 (52.9 to 80.9) | 100.0 (54.1 to 100.0) | 50.0 (11.8 to 88.2) |
Overall survival
| months | A(SHR-1210+Apatinib) | B(SHR-1210+Apatinib) | C(SHR-1210+Apatinib) |
|---|---|---|---|
| OS | 8.8 (4.9 to 12.3) | 11.2 (4.9 to NA) | 5.4 (1.5 to NA) |
Collected over 24 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A(SHR-1210+Apatinib) | 17/47 (36.2%) | 27/47 (57.4%) | 47/47 (100%) |
| B(SHR-1210+Apatinib) | 1/6 (16.7%) | 4/6 (66.7%) | 6/6 (100%) |
| C(SHR-1210+Apatinib) | 2/6 (33.3%) | 2/6 (33.3%) | 5/6 (83.3%) |
| Event | A(SHR-1210+Apatinib) | B(SHR-1210+Apatinib) | C(SHR-1210+Apatinib) |
|---|---|---|---|
| Aspartate aminotransferase increasedInvestigations | 3/47 | 2/6 | 0/6 |
| Alanine aminotransferase increasedInvestigations | 2/47 | 2/6 | 0/6 |
| HemoptysisRespiratory, thoracic and mediastinal disorders | 1/47 | 2/6 | 0/6 |
| DeathGeneral disorders | 9/47 | 1/6 | 0/6 |
| Progressive diseaseGeneral disorders | 6/47 | 0/6 | 1/6 |
| Platelet count decreasedInvestigations | 4/47 | 1/6 | 0/6 |
| Gamma-glutamyltransferase increasedInvestigations | 0/47 | 1/6 | 0/6 |
| Blood alkaline phosphatase increasedInvestigations | 0/47 | 1/6 | 0/6 |
| PneumoniaInfections and infestations | 3/47 | 1/6 | 0/6 |
| Respiratory tract infectionInfections and infestations | 0/47 | 1/6 | 0/6 |
| Event | A(SHR-1210+Apatinib) | B(SHR-1210+Apatinib) | C(SHR-1210+Apatinib) |
|---|---|---|---|
| HypertensionVascular disorders | 28/47 | 6/6 | 3/6 |
| Aspartate aminotransferase increasedInvestigations | 28/47 | 4/6 | 5/6 |
| AstheniaGeneral disorders | 13/47 | 3/6 | 4/6 |
| White blood cell count decreasedInvestigations | 20/47 | 4/6 | 2/6 |
| Neutrophil count decreasedInvestigations | 14/47 | 4/6 | 2/6 |
| Occult blood positiveInvestigations | 4/47 | 4/6 | 0/6 |
| VomitingGastrointestinal disorders | 6/47 | 1/6 | 3/6 |
| Alanine aminotransferase increasedInvestigations | 22/47 | 2/6 | 3/6 |
| Platelet count decreasedInvestigations | 20/47 | 3/6 | 1/6 |
| Blood creatinine increasedInvestigations | 6/47 | 3/6 | 1/6 |
| Age, Continuous(years) | A(SHR-1210+Apatinib) | B(SHR-1210+Apatinib) | C(SHR-1210+Apatinib) | Total |
|---|---|---|---|---|
| Mean | 60.3 ± 6.36 | 59.3 ± 7.39 | 54.2 ± 10.68 | 59.6 ± 7.08 |
| Sex: Female, Male(Participants) | A(SHR-1210+Apatinib) | B(SHR-1210+Apatinib) | C(SHR-1210+Apatinib) | Total |
|---|---|---|---|---|
| Female | 7 | 0 | 1 | 8 |
| Male | 40 | 6 | 5 | 51 |
| Race (NIH/OMB)(Participants) | A(SHR-1210+Apatinib) | B(SHR-1210+Apatinib) | C(SHR-1210+Apatinib) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 47 | 6 | 6 | 59 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | A(SHR-1210+Apatinib) | B(SHR-1210+Apatinib) | C(SHR-1210+Apatinib) | Total |
|---|---|---|---|---|
| China | 47 | 6 | 6 | 59 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Apr 2018 to primary completion in Aug 2021, 39 months.
Results were first posted in Aug 2024, 3 years after primary completion.
Of 54 industry-sponsored phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 44. This study's 39 months is above that.
Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Camrelizumab
Jiangsu HengRui Medicine Co., Ltd. →